William Blair Issues Positive Estimate for BEAM Earnings

Key Points

• William Blair has revised its Q3 2025 earnings estimates for Beam Therapeutics, forecasting a smaller loss of ($0.87) per share, up from a previous estimate of ($0.93).
• Beam Therapeutics reported a loss of ($1.00) per share in its latest quarter, which was better than the consensus estimate of ($1.04).
• The company currently has a market capitalization of $1.81 billion and a consensus rating of "Buy" from analysts, with a target price of $48.45.

Beam Therapeutics Inc. (NASDAQ:BEAM - Free Report) - Stock analysts at William Blair lifted their Q3 2025 earnings estimates for shares of Beam Therapeutics in a research report issued to clients and investors on Tuesday, August 5th. William Blair analyst S. Corwin now expects that the company will post earnings per share of ($0.87) for the quarter, up from their prior estimate of ($0.93). The consensus estimate for Beam Therapeutics' current full-year earnings is ($4.57) per share. William Blair also issued estimates for Beam Therapeutics' Q4 2025 earnings at ($0.87) EPS, FY2025 earnings at ($3.94) EPS, Q1 2026 earnings at ($0.88) EPS, Q2 2026 earnings at ($0.91) EPS, Q3 2026 earnings at ($0.92) EPS, Q4 2026 earnings at ($0.93) EPS and FY2026 earnings at ($3.64) EPS.

A number of other research analysts also recently commented on BEAM. Barclays reduced their price objective on shares of Beam Therapeutics from $25.00 to $21.00 and set an "equal weight" rating on the stock in a research note on Wednesday. Guggenheim reduced their price objective on shares of Beam Therapeutics from $78.00 to $55.00 and set a "buy" rating on the stock in a research note on Wednesday, May 7th. Cantor Fitzgerald upgraded shares of Beam Therapeutics to a "strong-buy" rating in a research note on Monday, July 21st. Finally, Wells Fargo & Company reduced their price objective on shares of Beam Therapeutics from $75.00 to $70.00 and set an "overweight" rating on the stock in a research note on Wednesday, May 7th. Two research analysts have rated the stock with a hold rating, nine have given a buy rating and three have given a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Buy" and an average target price of $48.45.

Beam Therapeutics Price Performance

BEAM traded down $0.24 during trading hours on Friday, reaching $17.62. 1,793,674 shares of the stock traded hands, compared to its average volume of 2,325,175. The firm's fifty day simple moving average is $18.84 and its two-hundred day simple moving average is $20.94. The company has a market cap of $1.78 billion, a price-to-earnings ratio of -3.92 and a beta of 2.22. Beam Therapeutics has a fifty-two week low of $13.52 and a fifty-two week high of $35.25.

Beam Therapeutics (NASDAQ:BEAM - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The company reported ($1.00) earnings per share for the quarter, beating analysts' consensus estimates of ($1.04) by $0.04. The business had revenue of $8.47 million during the quarter, compared to analyst estimates of $13.29 million. Beam Therapeutics had a negative net margin of 661.31% and a negative return on equity of 43.15%. The business's revenue was down 28.0% on a year-over-year basis. During the same period last year, the business earned ($1.11) EPS.

Institutional Trading of Beam Therapeutics

Several hedge funds have recently bought and sold shares of BEAM. ARK Investment Management LLC lifted its position in Beam Therapeutics by 20.0% in the 1st quarter. ARK Investment Management LLC now owns 8,480,089 shares of the company's stock valued at $165,616,000 after purchasing an additional 1,412,060 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in Beam Therapeutics by 72.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 3,026,701 shares of the company's stock valued at $59,112,000 after acquiring an additional 1,273,559 shares in the last quarter. Vanguard Group Inc. boosted its position in Beam Therapeutics by 16.4% during the 1st quarter. Vanguard Group Inc. now owns 8,871,292 shares of the company's stock worth $173,256,000 after acquiring an additional 1,249,303 shares during the period. EcoR1 Capital LLC bought a new position in shares of Beam Therapeutics in the first quarter worth $10,286,000. Finally, Woodline Partners LP increased its holdings in shares of Beam Therapeutics by 169.6% during the first quarter. Woodline Partners LP now owns 760,611 shares of the company's stock valued at $14,855,000 after purchasing an additional 478,491 shares during the period. 99.68% of the stock is currently owned by institutional investors.

Insider Activity

In other news, insider Fmr Llc sold 48,374 shares of the firm's stock in a transaction dated Wednesday, July 30th. The shares were sold at an average price of $20.50, for a total value of $991,667.00. Following the transaction, the insider directly owned 2,073,665 shares in the company, valued at approximately $42,510,132.50. This trade represents a 2.28% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. In the last 90 days, insiders have sold 49,624 shares of company stock valued at $1,015,628. Company insiders own 3.50% of the company's stock.

Beam Therapeutics Company Profile

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.